New BioMedicine Event Report
Provides in-depth analysis relating to an upcoming event for a select pipeline drug and forecasts the expected event outcome.
Subscribe to an RSS Feed Featured Reports
- New BioMedicine Special Event Report for Ariad Pharmaceuticals, Inc. (ARIA) - Data from the Phase II trial of Ridaforolimus for HER2 positive Metastatic Breast Cancer New BioMedicine - Oct 01, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Neurocrine Biosciences, Inc. (NBIX) - Top-line data from the third Phase IIb trial (Study 703 - Tulip Petal) of Elagolix for Endometriosis New BioMedicine - Sep 30, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Dyax Corp. (DYAX) - FDA approval of DX-88 for attacks of Hereditary Angioedema/HAE New BioMedicine - Sep 23, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Anadys Pharmaceuticals, Inc. (ANDS) - Preliminary data from the Phase II trial of ANA598 for Hepatitis C Virus (HCV) Infection New BioMedicine - Sep 21, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for BioSpecifics Technologies Corp.(BSTC) - FDA approval of Xiaflex for Dupuytren's Contracture New BioMedicine - Sep 18, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Theravance, Inc. (THRX) - FDA approval of Vibativ for Hospital-Acquired Pneumonia/HAP New BioMedicine - Sep 16, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Somaxon Pharmaceuticals, Inc. (SOMX) - FDA approval of Silenor for Insomnia New BioMedicine - Sep 11, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Endo Pharmaceuticals Holdings Inc. (ENDP) - FDA approval of Nebido for Male Hypogonadism New BioMedicine - Sep 10, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for Nektar Therapeutics (NKTR) - Data from the Phase II trial of NKTR-102 for Second-line Metastatic Ovarian Cancer New BioMedicine - Sep 07, 2009 - PDF - $40.00 - Add to Cart »
- New BioMedicine Special Event Report for NeurogesX, Inc. (NGSX) - FDA approval of Qutenza for Postherpetic Neuralgia/PHN New BioMedicine - Sep 04, 2009 - PDF - $40.00 - Add to Cart »
Samples
- New BioMedicine Special Event Report for Avanir Pharmaceuticals, Inc. (AVNR) - Phase III STAR trial data of Zenvia for Pseudobulbar Affect/PBA New BioMedicine - Jul 31, 2009 - PDF - View Report »